Pulse Biosciences, Inc. (NASDAQ:PLSE) Sees Significant Drop in Short Interest

Pulse Biosciences, Inc. (NASDAQ:PLSE) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 2,080,000 shares, a drop of 18.1% from the October 31st total of 2,540,000 shares. Currently, 12.2% of the company’s stock are sold short. Based on an average daily volume of 169,800 shares, the short-interest ratio is presently 12.2 days.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a report on Wednesday.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PLSE. Price T Rowe Associates Inc. MD bought a new stake in shares of Pulse Biosciences during the 1st quarter worth $88,000. Quest Partners LLC acquired a new stake in shares of Pulse Biosciences in the second quarter valued at about $91,000. Cetera Advisors LLC acquired a new stake in Pulse Biosciences in the 1st quarter valued at approximately $109,000. Rhumbline Advisers grew its stake in shares of Pulse Biosciences by 6.7% in the second quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after acquiring an additional 1,608 shares during the last quarter. Finally, Franklin Resources Inc. acquired a new stake in shares of Pulse Biosciences in the third quarter worth $378,000. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Stock Performance

Shares of PLSE stock traded up $1.03 on Friday, hitting $21.40. 123,050 shares of the stock traded hands, compared to its average volume of 202,033. The company’s fifty day moving average is $17.31 and its 200 day moving average is $15.77. Pulse Biosciences has a 1-year low of $6.59 and a 1-year high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period in the prior year, the firm earned ($0.19) earnings per share.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.